Target intelligence / Profile preview

C-terminal parathyroid hormone receptor (CPTHR) (CPTHR)

Target
CPTHR
Molecular classification
G protein-coupled receptor, Receptor
01

Overview

The C-terminal parathyroid hormone receptor (CPTHR) is a specialized receptor that specifically binds to the carboxyl-terminal fragments of parathyroid hormone (PTH), such as PTH(53-84) and PTH(39-84) (Divieti et al., 2001). While the well-characterized PTH1 receptor (PTH1R) mediates the classical calcemic actions of PTH via its N-terminal domain, the CPTHR appears to mediate distinct and often opposing biological effects, particularly in bone metabolism (Slatopolsky et al., 2000). It is predominantly expressed in osteoblasts and osteocytes, where it is thought to inhibit bone resorption and promote osteocyte survival (D'Amour, 2012). In clinical contexts, particularly chronic kidney disease (CKD), C-terminal PTH fragments accumulate significantly due to reduced renal clearance, potentially leading to skeletal resistance to PTH by competing for binding or exerting inhibitory effects through the CPTHR (Murray et al., 2005). Although the molecular identity of the CPTHR has been a subject of ongoing research and it has not been cloned as a unique gene, it is functionally classified as a G protein-coupled receptor (Bringhurst, 2002). Understanding this receptor is crucial for managing renal osteodystrophy and developing more precise therapies for metabolic bone diseases.

Other names
C-PTH receptorCPTH-RPTH-C receptorCarboxyl-terminal PTH receptor
02

Mechanism of action

Agonism of the CPTHR by C-terminal fragments of PTH, which modulates bone turnover and osteocyte activity, often opposing the actions of the PTH1 receptor (Slatopolsky et al., 2000; D'Amour, 2012).

03

Biological functions

Bone remodelingSignal transductionCalcium homeostasisOsteocyte survival
04

Disease associations

Chronic kidney diseaseRenal osteodystrophyOsteoporosisHypoparathyroidism
05

Safety considerations

Skeletal resistance to PTH in patients with chronic kidney disease (CKD)Potential for accumulation of inhibitory fragments in renal failure (Slatopolsky et al., 2000)
06

Interacting drugs

Parathyroid hormone (1-84)
07

Biomarkers

C-terminal PTH fragments (C-PTH)PTH(1-84)/C-PTH ratio

Beyond the preview

Go deeper on C-terminal parathyroid hormone receptor (CPTHR) (CPTHR).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on C-terminal parathyroid hormone receptor (CPTHR) (CPTHR).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call